Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2004-07-30
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Camptothecin; Irinotecan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma

• First relapse requires histologic confirmation of relapse

• No CNS metastases

• No lymphomatous meningitis

• Measurable disease

PATIENT CHARACTERISTICS:

Age:

• 15-75

Performance status:

• Zubrod 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Unless due to lymphoma:

• Platelet count at least 100,000/mm^3

• Absolute granulocyte count at least 1,500/mm^3

• Hemoglobin at least 9 g/dL

Hepatic:

• Bilirubin no greater than 1.5 mg/dL

• SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN if liver involvement)

Renal:

• Creatinine no greater than 2.0 mg/dL

• Baseline calcium less than 12 mg/dL

Cardiovascular:

• No myocardial infarction within 6 months

• No congestive heart failure requiring therapy

Other:

• No history of seizures

• No uncontrolled diabetes mellitus (i.e., random blood sugar of at least 250 mg)

• No other concurrent severe disease

• No uncontrolled infection

• HIV negative

• No psychoses

• No prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cancer of the cervix unless surgically treated and disease free for at least 5 years

• Not pregnant or lactating

• Effective contraception required of fertile patients

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior bone marrow transplantation

Chemotherapy:

• No more than 2 prior chemotherapy regimens for treatment of lymphoma

• No prior irinotecan, topotecan or aminocamptothecin

• At least 3 weeks since prior chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 3 weeks since prior radiotherapy

• Radiotherapy that is not a part of a combined-modality therapy is counted as a regimen (see Chemotherapy)

Surgery:

• Not specified

Other:

• No phenytoin, phenobarbital, or other antiepileptic prophylaxis